Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gestodene + ethinylestradiol
- Development stage
- Unknown
- Lead developer
- Effik
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carlin is a combined oral contraceptive (COC) developed by Effik, containing the synthetic progestogen gestodene and the synthetic estrogen ethinylestradiol. It is available in two dosage strengths: 75 mcg gestodene with either 20 mcg or 30 mcg ethinylestradiol. The drug functions primarily by inhibiting ovulation through the suppression of gonadotropin secretion (follicle-stimulating hormone and luteinizing hormone) from the pituitary gland. Additionally, it induces changes in the cervical mucus, making it less permeable to sperm, and alters the endometrium to reduce the likelihood of implantation. Carlin is approved for the prevention of pregnancy and is administered as a daily oral tablet.
- Brand names
- CarlinCarlin 75 mcg/20 mcgCarlin 75 mcg/30 mcg
- Other names
- gestodene/ethinylestradiolethinylestradiol + gestodene
02
Targets
GR (Glucocorticoid receptor)PR (Progesterone receptor)ESR1 (ERα)AR (Adrenergic receptors)GPER1 (G protein-coupled estrogen receptor 1)ESR2 (ERβ)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on gestodene + ethinylestradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gestodene + ethinylestradiol.